Date: 2011-04-19
Type of information: Licensing agreement
Compound: products containing a probiotic Lactobacillus strain
Company: Lonza (Switzerland) ORGANOBALANCE (Germany)
Therapeutic area: Nutrition
Type agreement: Licensing
Action mechanism:
Disease:
Details: Lonza and ORGANOBALANCE have signed a worldwide exclusive license agreement in which Lonza will develop, produce and commercialize products containing a probiotic Lactobacillus strain. Developed by ORGANOBALANCE GmbH, the probiotic strain acts against Helicobacter pylori. Research shows that H. pylori has been implicated as a common cause of peptic ulcers and gastritis. Currently, about 50 percent of the global population is infected with H. pylori (Source: Czinn SJ. J Pediatr. 2005 Mar;146 (3 Suppl):S21-6.). However, this new probiotic strain demonstrates great potential in helping to maintain a balanced H. pylori concentration. Utilizing a unique patentprotected mode of action, Lactobacillus anti-H. pylori binds to H. pylori in the stomach, thus creating large aggregates, which are subsequently flushed out of the stomach and excreted.
Financial terms:
Latest news:
